Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.

ABSTRACT:

Introduction

Few strategies exist for treatment of patients with small-cell lung cancer (SCLC) extended-stage after failure of first-line platinum-based chemotherapy. Lurbinectedin is a novel RNA-polymerase-II inhibitor investigated as a second-line therapy for SCLC. However, its efficacy and safety profile in real clinical practice remain to be determined.

Objective

To determine the efficacy and safety of lurbinectedin in real-life among patients with SCLC previously treated with first-line platinum-based chemotherapy.

Methods

We retrospectively evaluated patients who received at least one dose of lurbinectedin (3.2 mg/m² ) between March 2020 and November 2021, in the pulmonary department of Bordeaux University Hospital. Endpoints were time to treatment di

SUBMITTER: Toublanc AC 

PROVIDER: S-EPMC9346176 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature